AAREY DRUGS & PHARM LTD Fair Value
AAREYDRUGS · Healthcare · Current price ₹92.52
| Method | Fair value | Status |
|---|---|---|
| Residual income | ₹46 | 3% ROE fading to 13% over ~3 yrs, on ₹53 book |
| Relative P/E | ₹55 | EPS × 39.1 peer-median P/E |
| Graham floor | ₹41 | Conservative floor: √(22.5 × EPS × book value/share) |
| Analyst target | — | No analyst coverage |
Is AAREY DRUGS & PHARM LTD undervalued?
DocStoX estimates the fair value of AAREY DRUGS & PHARM LTD at ₹48 per share, versus the current market price of ₹93. That puts the stock about -48.4% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is high.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹46), Relative P/E (₹55), Graham floor (₹41). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹41 (bear) to ₹48 (base) to ₹55 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
More on AAREY DRUGS & PHARM LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.